H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $40 from $39 and keeps a Buy rating on the shares. The firm updated the company’s model post the 2025 earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Earnings Call Highlights Pipeline-Fueled Growth
- Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
- Genmab Launches DKK 725 Million Share Buy-Back to Cover RSU Commitments
- Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
- Genmab resumed with a Buy at Jefferies